"EMBOLD Study: New Data on 90+ MS Patients Expected in November"
Originally Published 2 years ago — by Multiple Sclerosis News Today

Atara Biotherapeutics plans to announce in November the one-year data from its EMBOLD Phase 1/2 study, which is testing the experimental treatment ATA188 for progressive forms of multiple sclerosis (MS). The data will cover the trial's primary endpoint of confirmed easing of disease-related disability, as well as other secondary clinical endpoints. ATA188 is designed to fight cells infected by the Epstein-Barr virus (EBV), a leading environmental risk factor for developing MS. The therapy uses immune T-cells obtained from healthy donors to target and attack EBV-infected immune cells in MS patients.
